MMRGlobal Announces Expansive Health IT Patent & Licensing Initiative

LOS ANGELES, CA--(Marketwire - Oct 9, 2012) -   MMRGlobal, Inc. (OTCBB: MMRF) (the "Company" or "MMR") today announced that it had received a Notice of Allowance, U.S. Serial No. 13/352,026 (the "NOA"), from the United States Patent and Trademark Office which expands the Company's "Method and System for Providing Online Medical Records." In short, the most recent allowed application expands MMR's patent portfolio to cover the exchange of protected health information to and from patients, doctors, pharmacies, insurance providers and other healthcare professionals in various forms, including, but not limited to, email, text, phone, facsimile and web-based portals. The MMR patent portfolio is believed to be relevant to virtually any provider who transmits electronic health records in that it will limit their ability to communicate protected health information without potentially infringing on MMR's patents. Starting in 2014, Meaningful Use requirements mandate that patients receive timely online access to their health information. The Company believes that the methods and systems claimed in its patent portfolio provide solutions which will assist healthcare providers in meeting those requirements.

The Company also announced that it has initiated licensing and enforcement efforts through its patent litigation counsel, Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP ("Liner"). Liner has already begun contacting physicians, hospitals, pharmacies and others who use or market methods and systems of providing personal health information including Personal Health Records to patients or healthcare professionals. 

According to Robert H. Lorsch, President and Chief Executive Officer of MMRGlobal, "We have invested heavily in the development of our patent portfolio and are now positioned to reap the benefits of such investment by compelling doctors, pharmacies, insurance providers, electronic medical record providers and other healthcare professionals to choose negotiating a license with us for the use of our intellectual property or face potential infringement actions. With Meaningful Use requirements for patient engagement taking effect in 2014, which stipulate that patients have online access to their medical records within a certain period of time following the receipt of healthcare services, we believe the MMR portfolio is extremely relevant."

"This Notice of Allowance continues to expand MMR's patent portfolio, which provides the Company with significant foundational intellectual property rights covering a large sector of health IT, particularly as it pertains to Personal Health Records," said Ted Ward, lead patent litigation counsel at Liner. "The Company has instructed us to begin enforcement of its intellectual property, and as a result, we have already begun contacting physicians, hospitals, pharmacies, and others who use or market methods and systems of providing Personal Health Records to patients or healthcare professionals. We are also pleased that this most recent application 13/352,026, which was filed on January 17, 2012, was issued in less than nine months. This Notice of Allowance, along with the Notice of Allowance of U.S. Serial No. 13/041,809 received approximately three weeks ago, continues to expand MMR's previously issued patents."

The MMR portfolio is the result of a six-year collaborative effort with the law firm of McKee, Voorhees & Sease, PLC ("MVS"), and the parties intend to continue to expand the reach of MMR's patent portfolio concurrently with the licensing and enforcement efforts of Liner. Any additional patents received by the Company will become part of its current patent portfolio, which already consists of U.S. patent numbers 8,117, 646; 8,117,045; and 8,121,855, announced earlier this year. According to John Goodhue of MVS, "We intend to continue doing our part in building out the MMR patent portfolio as quickly as possible so that MMR can continue to maximize the value of its IP in advance of the mandatory 2014 Meaningful Use requirements." 

The Company's patent portfolio also includes numerous other issued patents and pending applications in the U.S. and countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Canada, Hong Kong, Japan, South Korea, Israel, and European nations.

About MMRGlobal, Inc.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's products and services at

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, potential intellectual property enforcement actions, infringement claims, litigation or licenses, future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes of intellectual property enforcement actions, infringement claims, litigation or licensing transactions, results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033